Reaction
Blood Lactate Dehydrogenase Abnormal reporting signals
As of the last recalculation, Blood Lactate Dehydrogenase Abnormal appears in 664 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is ECULIZUMAB (PRR 137.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eculizumab | 176 | 137.8 | 138.2 |
| Brentuximab Vedotin | 17 | 53.3 | 53.4 |
| Bendamustine Hcl | 25 | 52.5 | 52.6 |
| Amphotericin B | 16 | 41.0 | 41.0 |
| Ruxolitinib | 82 | 40.8 | 40.8 |
| Ravulizumab | 13 | 30.7 | 30.8 |
| Cytarabine | 39 | 21.6 | 21.6 |
| Ifosfamide | 9 | 13.3 | 13.3 |
| Polatuzumab Vedotin | 4 | 12.9 | 12.9 |
| Pembrolizumab | 35 | 11.0 | 11.0 |
| Voxelotor | 5 | 7.0 | 7.0 |